These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 21125043)
1. Recent insights into the biology of bone turnover. Riches PL; Ralston SH J R Coll Physicians Edinb; 2010 Mar; 40(1):66-9. PubMed ID: 21125043 [No Abstract] [Full Text] [Related]
2. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Dempster DW; Lambing CL; Kostenuik PJ; Grauer A Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513 [TBL] [Abstract][Full Text] [Related]
3. [Osteoporosis and RANKL signal]. Nakamura M; Udagawa N Clin Calcium; 2011 Aug; 21(8):1149-55. PubMed ID: 21814019 [TBL] [Abstract][Full Text] [Related]
4. [New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody]. Wada S; Fukawa T; Kamiya S Nihon Rinsho; 2007 Nov; 65 Suppl 9():459-62. PubMed ID: 18161149 [No Abstract] [Full Text] [Related]
5. Denosumab for the treatment of osteoporosis and cancer-related conditions. Lewiecki EM; Bilezikian JP Clin Pharmacol Ther; 2012 Jan; 91(1):123-33. PubMed ID: 22158568 [TBL] [Abstract][Full Text] [Related]
6. Denosumab, osteoporosis, and prevention of fractures. Kiechl S; Willeit J; Schett G N Engl J Med; 2009 Nov; 361(22):2188-9; author reply 2190-1. PubMed ID: 19940304 [No Abstract] [Full Text] [Related]
7. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Wensel TM; Iranikhah MM; Wilborn TW Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432 [TBL] [Abstract][Full Text] [Related]
8. Denosumab, osteoporosis, and prevention of fractures. Blythe SL N Engl J Med; 2009 Nov; 361(22):2189-90; author reply 2190-1. PubMed ID: 19950410 [No Abstract] [Full Text] [Related]
9. Denosumab, osteoporosis, and prevention of fractures. Blackwood J N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950411 [No Abstract] [Full Text] [Related]
10. Osteoporosis treatment options expand. Mayo Clin Health Lett; 2010 Nov; 28(11):4. PubMed ID: 21158019 [No Abstract] [Full Text] [Related]
11. Treatment of osteoporosis with denosumab. Lewiecki EM Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778 [TBL] [Abstract][Full Text] [Related]
13. Denosumab (prolia) for postmenopausal osteoporosis. Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756 [No Abstract] [Full Text] [Related]
14. Denosumab, osteoporosis, and prevention of fractures. Kyrgidis A N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950409 [No Abstract] [Full Text] [Related]
15. The RANKL pathway and denosumab. Dore RK Rheum Dis Clin North Am; 2011 Aug; 37(3):433-52, vi-vii. PubMed ID: 22023901 [TBL] [Abstract][Full Text] [Related]
16. Study shows that a new type of osteoporosis drug reduces fracture risk. Harv Womens Health Watch; 2009 Oct; 17(2):6-7. PubMed ID: 19998553 [No Abstract] [Full Text] [Related]